The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A beta-lactam that is azetidin-2-one which is substituted at 1, 3, and 4 by p-fluorophenyl, 3-(p-fluorophenyl)-3-hydroxypropyl, and 4-hydroxyphenyl groups, respectively (the 3R,3'S,4S enantiomer).
Ezetimibe results in decreased activity of ABCB11 protein Ezetimibe inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
[Niacin co-treated with Ezetimibe co-treated with Simvastatin] results in increased expression of APOA1 protein; [Simvastatin co-treated with Ezetimibe] results in increased expression of APOA1 protein; Niacin promotes the reaction [[Simvastatin co-treated with Ezetimibe] results in increased expression of APOA1 protein]
[Ezetimibe co-treated with Simvastatin] results in decreased expression of CRP protein; [Simvastatin co-treated with Ezetimibe] promotes the reaction [Niacin results in decreased expression of CRP protein]
Ezetimibe results in decreased expression of NPC1L1 mRNA NPC1L1 exon SNP results in decreased susceptibility to Ezetimibe Ezetimibe results in decreased activity of NPC1L1 protein
[Metformin co-treated with rosiglitazone co-treated with Valsartan co-treated with Ezetimibe] inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TNF protein]; Ezetimibe inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TNF protein]
browse the term
